Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease

Medical Hypotheses

Volumn 71, Issue 1, 2008, Pages 156-157

  Borhani Haghighi, Afshin ^a   Safari, Anahid ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; BEHCET DISEASE; COMBINATION CHEMOTHERAPY; HUMAN; LETTER; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; HUMANS; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES; RECEPTORS, INTERLEUKIN-6;

EID: 44149120983     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.01.011     Document Type: Letter

References (13)

1. Borhani Haghighi A., Pourmand R., and Nikseresht A.R. Neuro-Behçet's disease: a review. The Neurologist 11 (2005) 80-89
2. Alty J.E., Monaghan T.M., and Bamford J.M. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFα blockade. Clin Neurol Neurosurg 109 3 (2007) 279-281
3. Borhani Haghighi A, Safari A. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Clin Neurol Neurosurg. doi:10.1016/j.clineuro.2007.10.005.
4. Wang C.R., Chuang C.Y., and Chen C.Y. Anticardiolipin antibodies and interleukin-6 In cerebrospinal fluid and blood of Chinese patients with neuro-Behçet's syndrome. Clin Exp Rheumatol 10 (1992) 599-602
5. Hirohata S., Isshi K., Oguchi H., et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behçet's syndrome. Clin Immunol Immunopathol 82 1 (1997) 12-17
6. Hirohata S., Suda H., and Hashimoto T. Low dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet's disease. J Neurol Sci 159 (1998) 181-185
7. Hatachi S., Nakazawa T., Morinobu A., et al. A pediatric patient with neuro-Behçet's disease. Mod Rheumatol 16 5 (2006) 321-323
8. Nakano Y., Hatanaka Y., Ikebuchi E., Shimizu T., Nanko S., and Utsumii T. A case of neuro-Behçet's disease with early onset of bipolar mood disorder. Seishin Shinkeigaku Zasshi 106 5 (2004) 564-573
9. Heyser C.J., Masliah E., Samimi A., Campbell I.L., and Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci USA 94 4 (1997) 1500-1505
10. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8 Suppl. 2 (2006) S2
11. Nishimoto N., Hashimoto J., Miyasaka N., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66 9 (2007) 1162-1167
12. Woo P., Wilkinson N., Prieur A.M., et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7 6 (2005) R1281-R1288
13. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54 9 (2006) 2817-2829